Abstract
Get full access to this article
View all access options for this article.
References
1.
Clinicaltrials.gov
. https://clinicaltrials.gov/ct2/results?term=stem+cell+therapy&Search=Search (last accessed
August
16 ,
2016 ) .
2.
Clinicaltrials.gov
. https://clinicaltrials.gov/ct2/results?term=gene+therapies&Search=Search (last accessed
August
16 ,
2016 ) .
3.European Medicines Agency (EMA) . Enhanced early dialogue to facilitate accelerated assessment of priority medicines (PRIME) EMA/CHMP/57760/2015 . London : EMA , 2016 .
4.EMA . Final report on the adaptive pathways pilot EMA/276376/2016 . London : EMA , 2016 .
5.EMA . User guide for micro, small and medium-sized enterprises EMA/860940/2011 . London : EMA , 2014
6.EMA . Best practice guidance for the parallel regulatory–HTA scientific advice procedure EMA/502692/2015 . London : EMA , 2016 .
7.EMA . Advanced therapy medicines: exploring solutions to foster development and expand patient access in Europe EMA/345874/2016 . London : EMA , 2016 .
8.U.S. Food and Drug Administration . www.fda.gov/forpatients/approvals/fast/ucm20041766.htm (last accessed
August
16 ,
2016 ) .
9.UK Medicines and Healthcare Products Regulatory Agency . Promising Innovative Medicine (PIM) Designation - Step I of Early Access to Medicines Scheme (EAMS) . www.gov.uk/government/uploads/system/uploads/attachment_data/file/375327/PIM_designation_guidance.pdf (last accessed
August
16 ,
2016 ) .
10.UK National Institute for Health and Care Excellence . NICE-MHRA scientific advice . www.nice.org.uk/about/what-we-do/scientific-advice/nice-mhra-scientific-advice (last accessed
August
16 ,
2016 ) .